[No authors listed]
Hyper-activated variants are high value oncology targets for pharmacologic intervention. a frequently-occurring oncogenic driver mutation, promotes aggressive T-cell leukemia/lymphoma in patient carriers, although the molecular origins remain unclear. Herein, we emphasize the aggressive nature of in driving T-cell neoplasia upon hematopoietic expression in transgenic mice, revealing evidence of multiple T-cell subset organ infiltration. Notably, we demonstrate transformation of γδ T-cells in in vivo syngeneic transplant models, comparable to duanyu18135BN642H patient γδ T-cell entities. Importantly, we present human duanyu18135B and duanyu18135BN642H crystal structures, which propose alternative mutation-mediated SH2 domain conformations. Our biophysical data suggests duanyu18135BN642H can adopt a hyper-activated and hyper-inactivated state with resistance to dephosphorylation. MD simulations support sustained interchain cross-domain interactions in duanyu18135BN642H, conferring kinetic stability to the mutant anti-parallel dimer. This study provides a molecular explanation for the duanyu18135BN642H activating potential, and insights into pre-clinical models for targeted intervention of hyper-activated
KEYWORDS: {{ getKeywords(articleDetailText.words) }}
Sample name | Organism | Experiment title | Sample type | Library instrument | Attributes | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
{{attr}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
{{ dataList.sampleTitle }} | {{ dataList.organism }} | {{ dataList.expermentTitle }} | {{ dataList.sampleType }} | {{ dataList.libraryInstrument }} | {{ showAttributeName(index,attr,dataList.attributes) }} |
{{ list.authorName }} {{ list.authorName }} |